TABLE 2.
Patient demographics and tumor characteristics
| Characteristic | Unmatched | Matched | ||||
|---|---|---|---|---|---|---|
| RL [n = 51] | OL [n = 145] | SMD | RL [n = 31] | OL [n = 31] | SMD | |
| Age, years [median (IQR)] | 59 (49–65) | 59 (53–67) | 0.24 | 59 (52–66) | 57 (52–63) | −0.18 |
| Male sex | 34 (67) | 100 (69) | 0.05 | 20 (65) | 17 (55) | −0.19 |
| BMI, kg/m2 [median (IQR)] | 25 (22–28) | 24 (22–26) | −0.52 | 25 (22–27) | 24 (22–26) | −0.18 |
| ASA score | ||||||
| ASA I/II | 28 (55) | 130 (90) | 1.14 | 20 (65) | 19 (61) | −0.07 |
| ASA III/IV | 23 (45) | 15 (10) | −1.14 | 11 (35) | 12 (39) | 0.07 |
| Previous abdominal surgery | 32 (63) | 54 (37) | −0.53 | 17 (55) | 17 (55) | 0.0 |
| Chemotherapy preoperatively | 23 (45) | 49 (34) | −0.24 | 14 (45) | 12 (39) | −0.13 |
| Region | ||||||
| West | 39 (76) | 32 (22) | −1.31 | 20 (65) | 19 (61) | −0.07 |
| East | 12 (24) | 113 (78) | 1.31 | 11 (35) | 12 (39) | 0.07 |
| Histopathology | ||||||
| Colorectal liver metastases | 23 (45) | 34 (23) | −0.51 | 13 (42) | 11 (35) | −0.13 |
| Hepatocellular carcinoma | 12 (24) | 96 (66) | 0.90 | 11 (35) | 14 (45) | 0.19 |
| Benign | 6 (12) | 1 (1) | −1.33 | 2 (6) | 1 (3) | −0.18 |
| Cholangiocarcinoma | 0 (0) | 3 (2) | 0.14 | 0 (0) | 0 (0) | NA |
| Other metastasis | 9 (18) | 8 (6) | −0.53 | 4 (13) | 5 (16) | 0.09 |
| Combined HCC/CCC | 1 (2) | 3 (2) | 0.01 | 1 (3) | 0 (0) | NA |
| Malignancy | 45 (88) | 144 (99) | 1.33 | 29 (94) | 30 (97) | 0.18 |
| Lesion origin | ||||||
| Metastatic | 32 (63) | 42 (29) | −0.74 | 17 (55) | 16 (52) | −0.06 |
| Primary | 13 (25) | 102 (70) | 0.98 | 12 (39) | 14 (45) | 0.13 |
| Benign | 6 (12) | 1 (1) | −1.33 | 2 (6) | 1 (3) | −0.18 |
Data are expressed as n (%) unless otherwise specified
ASA American Society of Anesthesiologists, BMI body mass index, CCC cholangiocarcinoma, HCC hepatocellular carcinoma, IQR interquartile range, OL open liver resection, RL robotic liver resection, SMD standardized mean difference, NA not available